All In Biotech

Drug Trial Radar · NCT05448001

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Last checked: Nov 19, 2026Latest source record: Aug 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 329 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

329

Actual

Start

Sep 19, 2022

Primary completion

Jul 10, 2024

Study completion Jul 19, 2024

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jul 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients with Gastric Ulcer

Conditions

  • Gastric Ulcer

Interventions

  • JP-1366 20mgDrug

    JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal

  • Lansoprazole 30mgDrug

    JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative complete healing rate for ulcer confirmed by upper gastrointestinal endoscopy by Week 8Time frame: Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Kuro Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.